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Abstract
Introduction: To report on efficacy, tolerability and safety of rituximab in children with refractory
autoimmune diseases.
Case presentation: Five patients (juvenile dermatomyositis, Wegener’s granulomatosis, systemic
lupus erythematosus, myasthenia gravis and multiple sclerosis with systemic lupus erythematosus)
were treated with rituximab and followed for a median time of 2.5 years. Two patients achieved
remission (systemic lupus erythematosus, Wegener’s granulomatosis). Three patients had a
refractory disease course and underwent autologous stem cell transplantation. Of those, two
achieved remission (juvenile dermatomyositis, myasthenia gravis), one died of complications after
transplantation (multiple sclerosis/systemic lupus erythematosus). No severe adverse events
occurred.
Conclusion: Efficacy of rituximab was variable ranging from complete remission to inefficacy.
Treatment was safe.
Introduction
B cells are considered to be major players in the
pathogenesis of most autoimmune diseases. B cells
produce antibodies and cytokines and are involved in
antigen presentation [1-2]. The chimeric anti-CD-20 anti-
body (rituximab [RTX]) leads to depletion of most
peripheral B-cells and has demonstrated a good efficacy
and safety profile in patients with rheumatoid arthritis
(RA) in randomized, double-blind, placebo controlled
trials [3]. RTX is approved in the USA and most European
countries for the treatment of RA after inefficacy of one
TNFa-blocking agent.
With regards to pediatric patients no randomized, placebo
controlled trials with RTX have been published so far.
Most available data are based upon case reports or
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with a small number of patients [3-9].
Here we report our experience on efficacy, tolerability and
safety in five pediatric patients treated with RTX for
refractory autoimmune diseases at our institution.
Informed consent was obtained from all patients and their
parents prior to treatment. Clinical and laboratory data
were evaluated retrospectively by chart review. The retro-
spective data acquisition was approved by the local Ethics
Committee of the University of Tuebingen.
Case presentations
Patient’s demographic and baseline characteristics are
summarized in Table 1.
RTX was applied according to the lymphoma protocol-
375 mg/m²/week over 4 weeks. Some of the patients
received also single RTX doses. Prior to every RTX infusion
single intravenous doses of prednisolone (1 mg/kg),
diphenhydrinate (2 mg total dose) and ranitidine
(150 mg total dose) were administered.
Case report 1
In 2003 the diagnosis of juvenile dermatomyositis (JDM)
was made in a 14 year old Caucasian girl (German). She
presented initially with typical JDM symptoms- heliotro-
pic rash, Gottron’s patches and loss of strength in the
proximal muscle groups. The muscle enzymes- creatine
kinase (CK) and aldolase (ALD)- were significantly
elevated. The patient also showed a slight elevation of
the inflammatory parameters erythrocyte sedimentation
rate (ESR) and C-reactive protein (CRP). The treatment
included: high doses of intravenous (i.v.) methylpredni-
solone (MP) (1 g/day for 3 days) and oral (p.o.)
prednisolone (PREDN) (2 mg/kg/day), i.v. methotrexate
(MTX) (1 mg/kg/week), i.v. immunoglobulins (IVIG)
(1 g/kg/day for 3 days) and oral cyclosporine A (CSA)
(3 mg/kg/day) (Table 1).
After two months of treatment CK and ALD normalized.
Nevertheless muscle strength decreased progressively and
after one year of treatment the girl was unable to move and
also showed difficulties in breathing and was incapable to
swallow hard food. At that time a slow but continuous
elevation of CK and ALD was observed. Also a diffuse
gadolinium enhancement on repeated whole-body mag-
netic resonance imaging scans (WBMRI) was documented.
Due to the persistent/progressive disease course and
considering the young age of the patient and also the
potential side effects of the immanent treatment with
cyclophosphamide (CYC) including ovarial suppression
by gonadotropin releasing hormone agonists, the indica-
tion for RTX was given.
TogetherwithMPpulses(1g/kg/dayfor3days),fourdoses
(1 course) of RTX were administered and the concomitant
medication with MTX (20 mg/m²/week subcutaneously)
wascontinued(Table1,Figure1).CKandALDnormalized
promptly. Muscle strength also improved to a little degree.
Improvement lasted for a total of six months. Immediately
thereafter muscle strength deteriorated again, CK and ALD
were again elevated and the patient received a second RTX
course together with MP pulses (1 g/day for 3 days) and
subcutaneous MTX (20 mg/m²/week) (Table 1, Figure 1).
CK and ALD normalized over the period of two months.
However, the muscle strength did not recover and the
patient was severely disabled. Due to this unsatisfying
response to RTX and the prominent myositic changes on
WB-MRI autologous stem cell transplantation (ASCT) was
performed, leading to complete drug free remission for
2.5 years by now.
Case report 2
In 2004 a ten year old Caucasian boy (German) was
diagnosed with Wegener’s granulomatosis. He was
treated for episcleritis with local antibiotics over the
period of three months and developed thereafter
recurrent fever attacks and a cough resistant to oral
antibiotics. He also complained of perioral skin ulcers,
knee- and hiparthralgia as well as an unexplained weight
loss of 10 kg. The chest X-ray showed peribronchial
infiltrates and patchy opacities in both upper lung fields
and the CT-scan revealed peribronchial, contrast
enhanced hyperdense areas. Laboratory investigation
showed a high ESR, CRP and elevated proteinase-3
anti-neutrophil cytoplasmatic antibodies (c-ANCA). Lung
biopsy revealed granulomatous, partially necrotic infil-
trates. Although there were no clear vasculitic signs this
result together with the clinical presentation and the
elevated c-ANCA supported the diagnosis of Wegener’s
granulomatosis. Other organs were not involved. Treat-
ment was started with i.v. MP (1 g/day for 3 days),
p.o. PREDN (2 mg/kg/day), i.v. CYC (750 mg/m²/every
4 weeks for 6 months) and p.o. azathioprine (AZA)
(3 mg/kg/day) (Table 1). Within eight weeks after treat-
ment initiation ESR and CRP reached normal levels (low
levels of c-ANCA persisted), skin changes disappeared
and chest X-ray showed a normal result. Due to the
clinical remission of the disease a slow tapering of the
oral steroids was started. Only two weeks after disconti-
nuing treatment with p.o. PREDN disease flared, evi-
denced by reoccurrence of cough, perioral and perianal
skin ulcers and also elevated CRP and ESR. Interestingly,
at that time the chest X-ray was normal. In order to
confirm or rule out lung involvement chest magnetic
resonance imaging (MRI) was used, which revealed
peribronchial hyperintense lesions with gadolinium
enhancement throughout both lungs. The young age
and the potential long-term side effects of multiple CYC
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(Table 1, Figure 1). The concomitant medication with
AZA was continued and oral PREDN (2 mg/kg/day) was
used as a bridging drug. This approach led to a resolution
of symptoms within 4 weeks. PREDN was tapered over
another 4 weeks, AZA was discontinued and remission
was sustained by mycophenolate mofetil (MMF; 1-2 g/
day depending on MMF blood levels; attempted: 2.5-
3.5 μg/ml). Three years later MMF was discontinued with
the patient still being in drug free remission.
Figure 1. B-cell depletion in patients 1 (JDM), 2 (WG), 4 (SLE/MG) and 5 (MS/SLE). No clear correlation between B-cell
recurrence and disease flares can be seen. In patient 4 (SLE/MG) B-cells were reduced below normal levels due to treatment
with cyclophosphamide. JDM, juvenile dermatomyositis; WG, Wegener’s granulomatosis; SLE, systemic lupus erythematodes;
MG, myasthenia gravis; MS, multiple sclerosis; ASCT, autologous stem cell transplantation; RTX, rituximab.
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In 1998 a 7 year old Caucasian boy (Turkish) was
diagnosed with systemic lupus erythematosus (SLE),
who initially presented with arthralgia, fatigue and malar
rash. Laboratory work-up showed an elevated ESR and
a normal CRP. Positive anti-dsDNA antibodies and a
proteinuria (750 mg/24h, normal 300 mg) were also
found. Renal biopsy proved lupus nephritis (WHO Grade
IV). No other organs were involved at that time. Treatment
with i.v. MP pulses (1 g/day for 3 days) and p.o. AZA
(3 mg/kg/day) was initiated, leading to reduction of the
proteinuria (350 mg/24h) and normalization of the ESR
whereas anti-dsDNA antibodies persisted. Due to incom-
pliance, the patient was only inconsistently seen by a
physician. Three years after the initial presentation the boy
was admitted to the Intensive Care Unit with loss of
consciousness and seizures. The MRI of the brain showed
subcortical hyperintense lesions, which were regarded as
SLE- related cerebral disease. Blood pressure was not
elevated and a hypertensive encephalopathy was not
considered as a possible cause for the cerebral changes
seen on MRI. The elevated ESR and the normal CRP as well
as the high levels of anti-dsDNA antibodies, were also
supporting the relation to SLE. Intravenous MP pulses
(1 g/day for 3 days), plasmapheresis and i.v. CYC
(750 mg/m² in a single dose) (Table 1) showed no effect
over the period of two weeks, neither clinically nor
serologically. At this point the decision for the experi-
mental use of antiCD20 antibody-treatment was made
and one single RTX dose was given. The patient slowly
regained consciousness over further two weeks and
inflammatory parameters normalized (there are no
records on anti-dsDNA antibody levels). Kidney function,
though, did not improve during the next two years and the
disease progressed to end-stage renal failure (creatinine
8 mg/dl, normal 1.2) requiring hemodialysis. Six years
later signs and symptoms of SLE were not present and
single kidney transplantation was performed. At that time
anti-dsDNA antibodies were not present.
Case report 4
In 1998 a 13 year old Caucasian girl (Russian), who was
diagnosed with SLE and later with myasthenia gravis
(MG), presented initially with pain and diffuse swelling of
the left leg. Doppler-ultrasonography was performed and
revealed deep venous thrombosis (DVT). The diagnosis
was supported by elevation of the d-dimers (highest values
4 μg/ml, normal up to 0.5) and therapy with low
molecular heparin was initiated. On further questioning
she reported the following symptoms which she had been
experiencing over the last three months: recurrent fever
attacks, increased sweating, fatigue, weight loss (5 kg) and
recurrent malar rash, which was not present at admission.
The laboratory work-up showed an elevated ESR, a normal
CRP and elevated anti-dsDNA antibodies (anti-cardiolipin
antibodies were negative). Apart from positive d-dimers
(due to the current thrombosis), other coagulation
parameters of the thrombophilic work-up were normal.
TreatmentwithAZA(3mg/kg/day)wasinitiated(Table1).
Oral PREDN (2 mg/kg/day) was administered as brid-
ging drug. Symptoms gradually disappeared and labora-
tory parameters including anti-dsDNA antibodies
normalized over the period of one year, leading to
remission of SLE.
Another year later, the patient complained of increasing
fatigue and excertional weakness. Examination showed
inability to hold raised arms and legs for more than
30 seconds and also fasciculations of the tongue, diplopic
images, which were impairing the vision and nasal speech.
Laboratory parameters (ESR, CRP, liver and kidney
function tests) including muscle enzymes were normal.
Anti-acetylcholine receptor (AChR) antibodies were ele-
vated and myasthenia gravis (MG) was diagnosed. The girl
was treated initially with i.v. MP pulses (1 g/day for
3 days), p.o. PREDN (2 mg/kg/day) and AZA (3 mg/kg/
day), which were insufficient to control disease activity of
MG (SLE was still in remission), with persistent loss of
muscle strength and impairment of the ability to perform
self-care during the next months. Medication was switched
to MMF (1-2 g/day - depending on MMF blood levels;
attempted: 3.5-4.5 μg/ml) and oral PREDN was continued
in various doses, which were adapted to the disease
activity. Pyridostigmine was administered during the
entire treatment period (Table 1). Under this medication
the patient regained her previous muscle strength allowing
her a normal daily life, which period lasted for approxi-
mately three years. After that time she presented with
symptoms of a new MG flare -impossibility to raise arms
and walk properly, diplopia and nasal speech. No clinical
or laboratory signs for active SLE disease were found.
In order to achieve control of MG six i.v. CYC pulses
(750 mg/m²/every 4 weeks) (Table 1) were administered.
Oral PREDN (various doses depending on the disease
activity of MG, up to 2 mg/kg/day) and pyridostigmine
(various doses adapted to muscle weakness) were con-
tinued as concomitant medication. Within the first two
months after the start of CYC treatment muscle strength
improved and the patient was able to walk again and to
perform self care with minor difficulties. Another severe
flare of MG (SLE was continuously in remission) occurred
seven months after the end of the treatment with CYC. The
aggravating muscular weakness could not be controlled by
the medication (including i.v. MP pulses, i.v. CYC at doses
previously described and plasmapheresis) and treatment
with RTX was initiated (Table 1). Despite two RTX courses
(Table 1, Figure 1), which were administered six months
apart, there was no clinical effect on MG symptoms and
further disease progression with continuous loss of muscle
strength was noted. Medication including i.v. MP pulses
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(3 mg/kg/day) and plasmapheresis did not influence the
progressive disease course and ASCT was performed.
During the first weeks after ASCT muscle weakness slowly
improved allowing the patient to walk again a few steps.
Three months after ASCT the improvement was inter-
rupted by another flare of MG with increasing fatigue,
impossibility to walk and rising AChR antibodies. A third
RTX course (after ASCT, Figure 1) was applied, leading to
complete remission of MG symptoms for more than
18 months now.
During the first RTX course only one episode of a mild
bronchitis occurred in that patient, which was successfully
handled with oral antibiotics in the outpatient clinic.
Case report 5
In 1991 a 3 year old Caucasian girl (Slovenian) was
diagnosed with multiple sclerosis (MS). She initially
presented with a slowly developing left sided hemiparesis
and bilateral vision impairment, which had occurred
within less than a month. Based on clinical presentation,
elevated cerebro-spinal fluid (CSF) total protein and
positive test for oligoclonal bands in the CSF multiple
sclerosis (MS) was diagnosed. Treatment included various
drugs including 12 i.v. CYC pulses (750 mg/m²/every
4 weeks) (Table 1). Despite treatment disease flared
several times over the next years leading to almost
complete visual loss. Repeated MRIs of the brain also
showed areas of persistent gadolinium enhancement
suggesting active disease. Due to the relapsing/progressive
disease course at the age of 12 years treatment with ß-
interferon was initiated, which led to clinical and MRI
remission over the next five years.
Attheageof17years,thepatientpresentedwithmalarrash,
fatigue and arthritis in both knees. Laboratory workup
showed an elevated ESR, high levels of anti-dsDNA
antibodies, slightly reduced complement factors C3 and
C4, which were suggestive for SLE. Supposing causality
betweentreatmentwithß-interferonanddruginducedSLE,
ß-interferonwasdiscontinuedandthepatientreceivedtwo
i.v. MP pulses (1 g/day for 3 days) and AZA (3 mg/kg/day)
(non-steroidal anti-inflammatory drugs were applied for
the arthritis) (Table 1) but without any effect, neither
clinically nor for the serological parameters.
Further i.v. MP pulses and p.o. PREDN (2 mg/kg/day)
were administered, yet without response concerning SLE
symptoms (MS was still in remission). The patient did
not respond to steroids and also discontinuation of
ß-interferon did not improve the pathologic condition,
therefore de novo SLE was supposed. Further therapeutic
considerations included treatment with CYC. The patient
had already received more than 25 g CYC in her life and
with respect to CYC- related longterm side effects RTX was
used (Table 1, Figure 1). SLE disease activity decreased
over the next three months: arthritis subsided, malar rash
was only slightly visible, ESR normalized, C3 and C4
normalized, although anti-dsDNA antibodies persisted.
On a regular check-up three months later renal insuffi-
ciency was noticed as reflected by reduction of the
creatinine clearance (60 ml/min; normal range 80-120)
and a slight elevation of the total urine protein (500 mg in
the 24 hours urine collection, normal below 300 mg).
Renal biopsy indicated WHO grade V nephritis. Treatment
with p.o. MMF (2-3 g/day -depending on MMF blood
levels; attempted: 3.5-4.5 μg/ml) was initiated, which had
no effect on the progressive renal involvement over the
next seven months leading to further reduction of the
creatinine clearance (lowest level at 36 ml/min). The latter
developed despite effective B-cell depletion (Figure 1).
Since the patient had already received multiple i.v. CYC
pulses ASCT was performed. Within the first four months
after ASCT malar rash vanished entirely, creatinine
clearance normalized (95 ml/min) and proteinuria
disappeared, anti-dsDNA antibodies were not detectable.
Two months later, the patient developed autoimmune
hemolytic anemia and thrombocytopenia, which was
considered as Evans syndrome. Other SLE symptoms
(clinically or in the laboratory work-up) were not present.
Another two single RTX doses had no effect on this aspect
of the disease and the patient required high doses of
i.v. MP (1 g/day for 3 days) and p.o. PREDN (2 mg/kg/
day) as well as repeated erythrocyte and platelet transfu-
sions. The condition deteriorated continuously and she
died of multiple organ failure due to severe uncontrollable
bleeding and hemolysis (Evans syndrome).
Immunoglobulin levels after treatment with rituximab
and B-cell reoccurrence
All patients had normal immunoglobulins before treat-
ment. In patient 1 (JDM), IgG, IgM and IgA-levels were
temporarily (over 6 months) reduced below normal range
without occurrence of infection. Patient 4 (SLE/MG) had
normal levels of all three immunoglobulin types during
the first and second RTX course. After the third course
(after ASCT) all three immunoglobulines dropped below
normal ranges, but in this case the effect on immunoglo-
bulin production cannot be assignedwith certaintyto RTX,
ASCT or both. All other patients had normal immunoglo-
bulin levels after RTX.
The median time for return of peripheral B-cells was
7.3 months (Table 1, Figure 1), although in patients 3-5
the influence of ASCT on B-cell production has to be taken
into account.
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Efficacy
Efficacy of RTX was variable in our patients. Patient 2
(WG) achieved remission (both clinically and serologi-
cally) after only one RTX course, subsequently sustained
with MMF, which was tapered after two years of treatment
without disease recurrence.
RTX has been effective for the treatment of pediatric
patients with SLE [5-6]. In patient 3 (SLE) cerebral disease
was regarded as SLE-related andprobably the combination
of RTX with immunosuppressive drugs was effective to
control cerebral disease [4]. Despite that therapy, kidney
disease progressed to end-stage renal insufficiency, requir-
ing haemodialysis and kidney transplantation later on.
Similarly, in patient 5 (MS/SLE) kidney disease was
progressive despite RTX and kidney function recovered
only after ASCT. After discontinuation of ß-interferon MS
was still inactive in that patient, which might be also
related to the treatment with RTX [10], but is most
probably the result of the combination treatment with
immunosuppressive drugs and ASCT. This patient devel-
oped Evans syndrome after ASCT, which was regarded as
SLE associated and died of its complications. With respect
to renal disease both cases are in contrast with published
data on successful application of RTX in children with SLE
related kidney disease [5-6].
RTX has also been effective for the treatment of JDM [7]. In
patient 1 (JDM) RTX only had a short lasting effect on the
JDM progression. It has to be mentioned that this patient
had a severe disease course and RTX was considered only
late during the treatment where disease progressed despite
RTX. The patient achieved a complete drug-free remission
after the ASCT.
In patient 4 (SLE/MG) RTX only had a minimal, short
lasting effect on the disease progression of MG (SLE was
inactive) before ASCT. Interestingly several months after
ASCT another MG flare occurred and RTX was applied.
This approach led to a complete remission in that patient.
In this case treatment success should probably be regarded
as a summary effect of both therapies.
Tolerability and safety
In our five patients, RTX was well tolerated. In contrast to
the published literature we could not observe infusion
related reactions or serum sickness [5], which is probably
due to the anti-allergic pre-treatment prior to every RTX-
infusion. Although infections have been related to RTX by
different authors [8-9], in our cohort only one episode of a
mild pulmonary infection occurred and was successfully
treated with oral antibiotics.
Immunoglobulins and B-cell depletion
A transient reduction of the levels of all three immuno-
globulin subtypes was found in two of our patients:
patient 1 (JDM) and patient 4 (SLE/MG). Decrease in
immunoglobulin levels was not associated with more
frequent infections and IVIG substitution was not under-
taken. Nevertheless, normal immunoglobulin levels in B-
cell depleted patients probably do not imply a normal
response to infection. Therefore in case of recurrent or
severe infections monitoring of all three immunoglobulin
types should be carried out and IVIG substitution
considered.
In the available literature immunoglobulins were reduced
in some of the patients, though none of them required
immunoglobulinsubstitutionduetotheselowlevels[6-8].
B-cell depletion lasted over a median time of 7.3 months
in our patient cohort without any clear correlation
between the B-cell depletion, B-cell recurrence, improve-
ment/remission and disease flares (Table 1 and Figure1), a
phenomenon already described in the literature [11].
Conclusion
Children with refractory autoimmune disorders often
require treatment with various combinations of immuno-
suppressants including high doses of steroids and cyclo-
phosphamide. These drugs may have significant side
effects and toxicity, especially when given over longer
periods of time. Representing a new therapeutic option
with a potentially lower rate of adverse events, rituximab
may be an important alternative and should be considered
alone or in combination treatment.
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